CRISPR Therapeutics Will Present Zugo-cel Trial Data
The company will share early results for its CD19-targeting gene-edited therapy on November 8, 2026.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you believe new gene-editing therapies will make treatment for serious diseases more accessible?
CRISPR Therapeutics is scheduled to present Phase 1 clinical data for zugocabtagene geleucel at the American College of Rheumatology Convergence 2026. This research-stage therapy uses gene-edited allogeneic CAR T cells to target CD19 in patients with refractory systemic sclerosis.
Why it matters
The presentation marks the latest application of the firm's gene-editing platform beyond its previously approved therapies for blood disorders. By targeting autoimmune disease, this research explores the efficacy of off-the-shelf CAR T cell therapies in conditions beyond oncology.
The clinical presentation is filed under abstract number 0225 for the ACR Convergence 2026 conference. This data reflects early Phase 1 results for the company's gene-edited allogeneic CAR T cell technology.
The players
CRISPR Therapeutics
A gene-editing company that utilizes the CRISPR/Cas9 platform to develop medical therapies, including the approved treatment CASGEVY.
The details
Zugocabtagene geleucel uses CRISPR/Cas9, a molecular tool that acts as a pair of genetic scissors to make precise cuts in DNA, to engineer allogeneic CAR T cells—immune cells modified to recognize and attack specific targets like CD19. These allogeneic cells are derived from healthy donors rather than the patient, which is intended to allow for immediate, off-the-shelf availability. The study investigates whether this method can effectively address systemic sclerosis, a condition characterized by immune-driven tissue fibrosis.
Timeline
November 8, 2026, 10:30 a.m. ET: CRISPR Therapeutics presents zugo-cel clinical data.
The Tech Race
This research extends the company's clinical pipeline beyond the regulatory milestone of its approved CASGEVY therapy. It represents a pivot toward applying validated gene-editing methods to the complex landscape of refractory autoimmune conditions.
This development remains in the research phase and does not currently impact medical treatment availability or standard patient care workflows. Potential future clinical utility for patients with refractory systemic sclerosis depends on the results of ongoing trials and subsequent regulatory review.
The takeaway
This trial represents the next stage in evaluating whether CRISPR-edited CAR T cells can address autoimmune diseases effectively. Observers should track the release of abstract 0225 on November 8, 2026, to assess the reported efficacy markers.
What happens next
A copy of the presentation will be available on the company website following the conclusion of the session on November 8, 2026.
Further reading
For more developments in gene-editing applications, visit Biotech.
More information
View the latest Company investor and clinical information regarding ongoing research programs.
Live Poll
Do you believe new gene-editing therapies will make treatment for serious diseases more accessible?
